Enjoy complimentary customisation on priority with our Enterprise License!
The breast cancer monoclonal antibodies market size is forecast to increase by USDUSD 19.2 billion at a CAGR of 13.97% between 2023 and 2028. The breast cancer market is witnessing significant growth due to the increasing prevalence of breast cancer and the approval of an expanding product pipeline for monoclonal antibody (mAb) drugs. These therapies, which target specific proteins on cancer cells, are becoming increasingly popular as systemic treatments for breast cancer, particularly for those with hormonal receptors, such as estrogen receptor (ER) and progesterone receptor (PR) positive tumors. Additionally, the identification of BRCA gene mutations has led to the development of mAb drugs that specifically target these mutations, further expanding the market. However, the high cost of mAb treatments compared to traditional therapies remains a challenge for patient access and market penetration.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.